Immune System News and Research

RSS

Exposure to deadly bacteria can result in stillbirths

A new study shows the risk for severe effects of exposure to Listeria monocytogenes among susceptible populations may occur at doses lower than suggested by previous studies.

13 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

IACC to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research

Autism Speaks is encouraged by yesterday's decision of the Interagency Autism Coordinating Committee (IACC) to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research. The new language, approved unanimously, calls for studies to determine if there are sub-populations that are more susceptible to environmental exposures such as immune challenges related to naturally occurring infections, vaccines or underlying immune problems.

12 Nov 2009

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children

CSL Biotherapies, a subsidiary of CSL Limited, one of the world’s leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

EMS Solutions provides free resources to help companies tackle this year's H1N1 flu pandemic

Emergency Management & Safety Solutions (EMS Solutions), the crisis planner for many Fortune 100 companies, international government agencies and large non-profit organizations, is providing free resources to help companies better prepare for and prevent transmission of this year's H1N1 flu pandemic. Today, over 180 countries have experienced the H1N1 virus outbreak and approximately 6,500 people have died -- including over 1,500 in North America, according to the European Center for Disease Prevention and Control.

12 Nov 2009

U.S. Patent and Trademark Office awards new patent for Ryogen

Ryogen LLC, a genomic start-up company, has been awarded a new patent titled “Isolated Genomic Polynucleotide Fragments from Chromosome 7”.

12 Nov 2009

Bend Memorial Clinic to begin Phase III lung cancer trial

The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

11 Nov 2009

Also in global health news: RUTF; global hunger; preventing natural disasters; El Salvador floods

"Rich nations should do more to help vulnerable countries prepare for natural disasters if they want their stretched humanitarian funds to go further during the economic downturn, a report said Tuesday," Reuters/New York Times reports

11 Nov 2009

Pan-African conference to focus on the rapid growth of diabetes in Africa

The Republic of Mauritius in collaboration with the World Health Organization Afro Region and the International Diabetes Federation (IDF) today opened an International Conference on Diabetes & Associated Diseases in Port Louis, Mauritius to highlight their concern about the rapid growth of the diabetes epidemic throughout Africa. The conference will run from November 12 and end on November 14 – World Diabetes Day.

11 Nov 2009

New policies to decrease the public's exposure to EDCs; AMA to work with federal government

The American Medical Association's (AMA) House of Delegates adopted a resolution calling on the AMA to work with the federal government to enact new federal policies to decrease the public's exposure to endocrine-disrupting chemicals (EDCs).

11 Nov 2009

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Immune System News and Research

Exposure to deadly bacteria can result in stillbirths

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

IACC to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children

Nuvo Research announces new licensing agreement for Oxoferin

EMS Solutions provides free resources to help companies tackle this year's H1N1 flu pandemic

U.S. Patent and Trademark Office awards new patent for Ryogen

Bend Memorial Clinic to begin Phase III lung cancer trial

Also in global health news: RUTF; global hunger; preventing natural disasters; El Salvador floods

Pan-African conference to focus on the rapid growth of diabetes in Africa

New policies to decrease the public's exposure to EDCs; AMA to work with federal government

Lower socioeconomic status linked with inability to fight H1N1

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

NIDA supports new drug detection research

Common myths about sun exposure, sunscreen and vitamin D

Aduro BioTech raises funds through its Series A-1 financing

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News